209 related articles for article (PubMed ID: 18801532)
1. Prostate specific antigen assay standardization bias could affect clinical decision making.
Loeb S; Chan DW; Sokoll L; Kan D; Maggiore J; Mikolajczyk SD; Mondo DM; Griffin CR; Catalona WJ
J Urol; 2008 Nov; 180(5):1959-62; discussion 1962-3. PubMed ID: 18801532
[TBL] [Abstract][Full Text] [Related]
2. Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specific antigen.
Sotelo RJ; Mora KE; Pérez LH; Novoa J; Carmona O; De Andrade R; Borges RE; Parada D; Loeb S; Catalona WJ
Urology; 2007 Jun; 69(6):1143-6. PubMed ID: 17572203
[TBL] [Abstract][Full Text] [Related]
3. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
[TBL] [Abstract][Full Text] [Related]
4. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.
Loeb S; Roehl KA; Nadler RB; Yu X; Catalona WJ
J Urol; 2007 Dec; 178(6):2348-52; discussion 2352-3. PubMed ID: 17936844
[TBL] [Abstract][Full Text] [Related]
5. Mass screening for prostate cancer in Korea: a population based study.
Song C; Ahn H; Lee MS; Park J; Kwon TG; Kim HJ; Choi HY;
J Urol; 2008 Nov; 180(5):1949-52; discussion 1952-3. PubMed ID: 18801541
[TBL] [Abstract][Full Text] [Related]
6. Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.
Meeks JJ; Thaxton CS; Loeb S; Roehl KA; Helfand BT; Catalona WJ
J Urol; 2008 Apr; 179(4):1340-3. PubMed ID: 18289590
[TBL] [Abstract][Full Text] [Related]
7. Prostate specific antigen velocity threshold for predicting prostate cancer in young men.
Loeb S; Roehl KA; Catalona WJ; Nadler RB
J Urol; 2007 Mar; 177(3):899-902. PubMed ID: 17296371
[TBL] [Abstract][Full Text] [Related]
8. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
Moul JW; Sun L; Hotaling JM; Fitzsimons NJ; Polascik TJ; Robertson CN; Dahm P; Anscher MS; Mouraviev V; Pappas PA; Albala DM
J Urol; 2007 Feb; 177(2):499-503; discussion 503-4. PubMed ID: 17222618
[TBL] [Abstract][Full Text] [Related]
9. The association between total prostate specific antigen concentration and prostate specific antigen velocity.
Yu X; Loeb S; Roehl KA; Han M; Catalona WJ
J Urol; 2007 Apr; 177(4):1298-302; discussion 1301-2. PubMed ID: 17382716
[TBL] [Abstract][Full Text] [Related]
10. Defining increased future risk for prostate cancer: evidence from a population based screening cohort.
Schröder FH; Roobol MJ; Andriole GL; Fleshner N
J Urol; 2009 Jan; 181(1):69-74; discussion 74. PubMed ID: 19012915
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
[TBL] [Abstract][Full Text] [Related]
12. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies.
Stephan C; Kramer J; Meyer HA; Kristiansen G; Ziemer S; Deger S; Lein M; Loening SA; Jung K
BJU Int; 2007 Jun; 99(6):1427-31. PubMed ID: 17355366
[TBL] [Abstract][Full Text] [Related]
13. Multicenter evaluation of an investigational prostate cancer methylation assay.
Baden J; Green G; Painter J; Curtin K; Markiewicz J; Jones J; Astacio T; Canning S; Quijano J; Guinto W; Leibovich BC; Nelson JB; Vargo J; Wang Y; Wuxiong C
J Urol; 2009 Sep; 182(3):1186-93. PubMed ID: 19625061
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer risk assessment program: a 10-year update of cancer detection.
Giri VN; Beebe-Dimmer J; Buyyounouski M; Konski A; Feigenberg SJ; Uzzo RG; Hanks G; Godwin AK; Chen DY; Gordon R; Cescon T; Raysor S; Watkins-Bruner D
J Urol; 2007 Nov; 178(5):1920-4; discussion 1924. PubMed ID: 17868726
[TBL] [Abstract][Full Text] [Related]
15. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
16. Percent free prostate specific antigen does not enhance the specificity of total prostate specific antigen for the detection of prostate cancer in Korean men 50 to 65 years old: a prospective multicenter study.
Jeong IG; Lee KH;
J Urol; 2008 Jan; 179(1):111-6. PubMed ID: 17997422
[TBL] [Abstract][Full Text] [Related]
17. Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
Ito K; Yamamoto T; Miyakubo M; Takechi H; Ohi M; Shibata Y; Suzuki K
J Urol; 2007 Oct; 178(4 Pt 1):1258-63; discussion 1263-4. PubMed ID: 17698107
[TBL] [Abstract][Full Text] [Related]
18. Total prostate specific antigen stability confirmed after long-term storage of serum at -80C.
Reed AB; Ankerst DP; Leach RJ; Vipraio G; Thompson IM; Parekh DJ
J Urol; 2008 Aug; 180(2):534-7; discussion 537-8. PubMed ID: 18550121
[TBL] [Abstract][Full Text] [Related]
19. An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics.
Stephan C; Cammann H; Meyer HA; Müller C; Deger S; Lein M; Jung K
BJU Int; 2008 Sep; 102(7):799-805. PubMed ID: 18522632
[TBL] [Abstract][Full Text] [Related]
20. Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2 to 10 ng/ml.
Pelzer AE; Bektic J; Akkad T; Ongarello S; Schaefer G; Schwentner C; Frauscher F; Bartsch G; Horninger W
J Urol; 2007 Jul; 178(1):93-7; discussion 97. PubMed ID: 17499288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]